Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated by Analysts at began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note issued to investors on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock. Nabriva Therapeutics Trading Down 7.1 % NASDAQ NBRV opened at $0.13 on Friday. The company has a debt-to-equity ratio of 0.12, a current […]

Leave a Reply

Your email address will not be published.

Previous post Downgrades Cabot (NYSE:CBT) to Buy
Next post SoFi Technologies (NASDAQ:SOFI) Price Target Cut to $11.00